Back to Browse Journals » Neuropsychiatric Disease and Treatment » Volume 2 » Issue 3

Religiosity in patients with Parkinson's disease

Authors Patrick McNamara, Raymon Durso, Ariel Brown

Published 15 September 2006 Volume 2006:2(3) Pages 341—348

Patrick McNamara, Raymon Durso, Ariel Brown

Department of Neurology, Boston University School of Medicine, Boston, MA, and VA Boston Healthcare System, Boston, MA, USA

Objective: To study clinical correlates of religiosity in Parkinson’s disease (PD).

Methods: Measures of life goals, religiosity, mood, and neuropsychologic function were assessed in 22 persons with mid-stage PD and 20 age-matched healthy controls. Levodopa dose equivalents (LDE) were also computed for the patients.

Results: Relative to other major life goals parkinsonian patients were significantly more likely to report that “my religion or life philosophy” was less important than were age-matched controls. Scores on a battery of religiosity scales were consistently lower for Parkinson’s patients than those of age-matched controls. While Mini Mental State Exam, logical memory recall, Stroop, and selected (depression and anxiety) mood scales reliably distinguished patients from controls, only measures of prefrontal function correlated with religiosity scores.

Conclusions: Patients with PD express less interest in religion and report consistently lower scores on measures of religiosity than age-matched controls. Prefrontal dopaminergic networks may support motivational aspects of religiosity.

Keywords: religiosity, Parkinson’s disease, neuropsychology, mood, executive functions, dopamine agonists

Download Article [PDF] 

Readers of this article also read:

High-sensitivity C-reactive protein, lipoprotein-related phospholipase A2, and acute ischemic stroke

Kara H, Akinci M, Degirmenci S, Bayir A, Ak A, Nayman A, Unlu A, Akyurek F, Sivri M

Neuropsychiatric Disease and Treatment 2014, 10:1451-1457

Published Date: 6 August 2014

Enrichment of breast cancer stem-like cells by growth on electrospun polycaprolactone-chitosan nanofiber scaffolds

Sims-Mourtada J, Niamat RA, Samuel S, Eskridge C, Kmiec EB

International Journal of Nanomedicine 2014, 9:995-1003

Published Date: 19 February 2014

Long-acting preparations of exenatide

Cai Y, Wei L, Ma L, Huang X, Tao A, Liu Z, Yuan W

Drug Design, Development and Therapy 2013, 7:963-970

Published Date: 5 September 2013

Visuomotor competencies and primary monosymptomatic nocturnal enuresis in prepubertal aged children

Esposito M, Gallai B, Parisi L, Roccella M, Marotta R, Lavano SM, Mazzotta G, Patriciello G, Precenzano F, Carotenuto M

Neuropsychiatric Disease and Treatment 2013, 9:921-926

Published Date: 26 June 2013

Cyclin D1 affects epithelial–mesenchymal transition in epithelial ovarian cancer stem cell-like cells

Jiao J, Huang L, Ye F, Shi MF, Cheng XD, Wang XY, Hu DX, Xie X, Lu WG

OncoTargets and Therapy 2013, 6:667-677

Published Date: 20 June 2013

Profile of blonanserin for the treatment of schizophrenia

Tenjin T, Miyamoto S, Ninomiya Y, Kitajima R, Ogino S, Miyake N, Yamaguchi N

Neuropsychiatric Disease and Treatment 2013, 9:587-594

Published Date: 29 April 2013

Beneficial effect of pramipexole for motor function and depression in Parkinson’s disease

Osamu Kano, Ken Ikeda, Tetsuhito Kiyozuka, Konosuke Iwamoto, Hirono Ito, et al

Neuropsychiatric Disease and Treatment 2008, 4:707-710

Published Date: 8 August 2008

Editorial: Treatment of generalized anxiety disorder || FREE PAPER ||

Roger M Pinder

Neuropsychiatric Disease and Treatment 2007, 3:183-184

Published Date: 15 May 2007

Marked effect of milnacipran combined with olanzapine for a delusional depressive patient

Yuka Sugawara, Hisashi Higuchi, Keizo Yoshida, Tetsuo Shimizu

Neuropsychiatric Disease and Treatment 2005, 1:373-374

Published Date: 15 December 2005